Market Overview

HCP Gets Bullish Commentary From Goldman Sachs

HCP Gets Bullish Commentary From Goldman Sachs
Related HCP
Raymond James Picks Welltower, Sabra Health In Underweighted Health Care REIT Sector
Benzinga's Top Upgrades, Downgrades For May 21, 2018
Recession Proof REIT - 7.7% Yield And 40% Upside (Seeking Alpha)

HCP, Inc. (NYSE: HCP) announced plans of a tax-free spinoff of its skilled nursing portfolio. Goldman Sachs’ Andrew Rosivach upgraded the rating on the company from Sell to Neutral, while raising the price target from $26 to $36. The analyst commented that the spinoff would result in an increased focus on the value of HCP on a sum-of-the-parts [SOTP] basis.

“After making a series of adjustments to run rate operating income (reducing skilled nursing, increasing senior housing operating) and cap rates to peers (higher for skilled nursing, lower for hospitals), we estimate HCP trades at a modest 8% discount to peers on an SOTP basis,” analyst Andrew Rosivach wrote. He added that the in case the spin does happen, it would highlight this gap.


Since being added to the Americas Sell List on September 21, 2015, HCP’s shares have declined by 10 percent, versus a 7 percent gain in the S&P 500 and a 16 percent gain in RMZ over the same period, Rosivach pointed out.

Related Link: Morgan Stanley Downgrades WellTower, HCP: "Is Triple Net Sr. Housing The Next Shoe To Drop?"

HCP’s shares currently trade at a 10 percent discount to the Healthcare REIT coverage average and at a 30 percent discount to the REIT coverage average.

“We believe the steep discount on this basis [SOTP] will offset challenges in external growth, lease coverage, and tenant concentration,” the analyst wrote.

Latest Ratings for HCP

May 2018Raymond JamesDowngradesOutperformMarket Perform
May 2018Evercore ISI GroupDowngradesIn-LineUnderperform
Mar 2018Wells FargoMaintainsMarket PerformMarket Perform

View More Analyst Ratings for HCP
View the Latest Analyst Ratings

Posted-In: Andrew Rosivach Goldman SachsAnalyst Color Upgrades Price Target Analyst Ratings Best of Benzinga


Related Articles (HCP)

View Comments and Join the Discussion!